Harpoon Tx - HARP Net earnings per share for the last four quarters

Official company branding of Harpoon Tx (HARP)

Acquisition by a pharma behemoth neutralized the pre-commercial risks of Harpoon Therapeutics (HARP). The development of T-cell-based targeted therapies against solid tumors reduced pipeline threats, although dependence on external investment and the probability of clinical failures maintained uncertainty. The rolling annual growth rate of net income per share demonstrates the outcome of these processes, where the value of 60.10 determines the status of the parameter.

Harpoon Therapeutics, Inc. (HARP) Earnings per share for the last twelve months: for the period 02/11/2024 - 02/20/2024

HARP (Harpoon Therapeutics, Inc.): analytical breakdowns and indicator data

Initial company analysis:HARP, Harpoon Tx
Mass-produced product of harpoontx.com

Harpoon Therapeutics (HARP) is optimizing costs by utilizing external contract laboratories instead of its own plants. This fabless model is directly reflected in the annual change in net income per share over a rolling period. The metric measures EPS TTM dynamics, allowing for a daily assessment of business efficiency without waiting for quarterly reports. While the positive trend confirms growing profitability, the issuer's hidden risks could trigger sharp drawdowns.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ALX Oncology Holdings Inc.|CUE: Net earnings per share (EPS TTM)|PDS Biotech - Earnings per share for the trailing year|SONN (Sonnet BioTherapeutics Holdings Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MAIA Biotech|Earnings per share for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Earnings per one share for the last 12 months|NextCure Inc - Net earnings per share for the last 12 months|Leap Therapeutics, Inc. (LPTX) - Net earnings per one share for the last twelve months|Intensity Therapeutics Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters senseibio.com SNSE|TOVX: Net earnings per share (EPS TTM)|Gritstone bio Inc. - Earnings per share for the trailing year|Net earnings per share for the last 12 months KA|Earnings per share for the last 12 months NEXI (NexImmune, Inc.)|Earnings per share for the last twelve months Turnstone Biologics Corporation (TSBX)|Net earnings per share for the last 12 months Vaccinex VCNX